- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06027970
Efficacy of Continuous Terlipressin Therapy After Endoscopic Variceal Ligation (TERLEVL)
Efficacy of Continuous Terlipressin Therapy After Endoscopic Variceal Ligation in Acute Variceal Haemorrhage: A Randomised Control Clinical Trial
Upper gastrointestinal (UGI) bleed of variceal origin is a common medical emergency. Prompt endoscopic variceal ligation (EVL) is therapeutic as well as diagnostic. Terlipressin, a vasopressin analog (intravenous, 2 mg q 4 hourly), is widely used promptly in any suspicious cases of variceal haemorrhage (VH) before endoscopic intervention, along with volume and blood resuscitative measures.
As per guideline, after EVL Terlipressin therapy (1 mg IV q 4 hourly) is advised to continue for 2-5 day to prevent re-bleed and mortality [1]. But the prolong use of Terlipressin is not completely safe as well as it is expensive also in resource constraint setting. At present, no randomized control clinical trial (RCT) is available to prove the efficacy of post-EVL Terlipressin therapy in preventing re-bleed and mortality in acute variceal haemorrhage.
During the post marketing surveillance Terlipressin therapy was found to be associated with life threatening complication like cardiac arrhythmia, myocardial ischemia, critical vasoconstriction of peripheral as well as internal organ leading to ischemia or gangrene, severe hyponatremia, hypertension, fluid overload and pulmonary oedema (2-4).
So the justification of continuing Terlipressin for 5 days after EVL is questionable, as the haemostasis is primarily achieved by EVL and the risk versus benefit of Trelipressin therapy after EVL is still unknown. Continue IV Terlipressin therapy also prolongs in-hospital care causing further increase of health care burden.
As per recently concluded institutional study, continuing Terlipressin after EVL in acute VH did not prevent re-bleed or mortality, rather it increased the risk of ADR, duration of hospital stay, in-hospital complications and cost of the therapy [5]. But the study was open level with relatively smaller sample size.
There is still lack of RCT on post-EVL Terlipressin therapy, regarding its efficacy in preventing re-bleed and mortality. So, we have planned this study to evaluate the efficacy of continuous Terlipressin therapy after EVL, in acute VH.
It will be a double blind randomized controlled clinical trial. The study will be carried out in the 2 arms; denoting the duration of Terlipressin therapy after EVL. Participant with acute VH will be randomized into two study groups after successful EVL.
The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days and the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days. Both the group will receive standard care of therapy and will be followed up for 8 weeks. The participants and the recruiter/PI will be unaware of intervention (terlipressin or NS) receiving.
The study will enlighten us regarding efficacy of continuous Terlipressin therapy after EVL to prevent re- bleed and mortality in acute VH. The study will also generate significant data regarding adverse drug events (ADE) and cost effectiveness or pharmaco- economics of continue Terlipressin therapy after EVL.
In the Indian population there is no study to determine the role gene related to variceal bleed or re-bleed. Endothelial dysfunction is the major contributor for the development of portal hypertension and subsequent varices formation in patient with cirrhosis. Development of blood vessel and endothelial function, endothelial proliferation and neoangiogenesis are regulated by vascular endothelial growth factor (VEGF) family genes. In a recently published study, VEGF C(+405)G(rs2010963) single nucleotide polymorphism (SNP) genotype was found to be associated with higher risk of esophageal and gastric varices and bleeding [10]. Since VEGF is the major factor to endothelial proliferation and neoangiogenesis. So, in this study, as a secondary objective, we will also try to explore the association of VEGF genotype with variceal bleed/ re-bleed and mortality.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Deba P Dhibar, MD
- Phone Number: 9530881462
- Email: drdeba_prasad@yahoo.co.in
Study Locations
-
-
-
Chandigarh, India, 160012
- Department of Internal Medicine, Post Graduate Institute of Medical Education and Research,
-
Contact:
- P
- Phone Number: +911722756670
- Email: pgimerinternalmed@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Irrespective of gender
- age ≥ 18 years
- all the patients with endoscopy proven acute VH with successful EVL done
Exclusion Criteria:
- Patients not receiving pre-EVL Terlipressin therapy
- not achieving haemostasis during EVL
- EVL done beyond 48 hours of admission because of hemodynamic instability or encephalopathy
- Patients with chronic kidney disease
- Patients with pregnancy
- Patients who are receiving blood thinners like anti-platelets, anti-coagulation agents within 4 weeks of presentation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment
After successful Endoscopic variceal ligation (EVL) the treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days.
Both the group will receive standard care of therapy.
|
After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
Other Names:
|
Placebo Comparator: Control
After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days.
Both the group will receive standard care of therapy.
|
After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Re-bleed
Time Frame: 7 days
|
Re-bleed is defined as any significant UGI haemorrhage after EVL, leading to repeat endoscopy, haemodynamic instability and significant drop of haemoglobin requiring blood transfusion.
|
7 days
|
Mortality
Time Frame: 7 days
|
Incidence of episode of mortality
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of hospital stay
Time Frame: 1 week
|
Number of days of stay in the hospital
|
1 week
|
need for blood transfusions
Time Frame: 1 week
|
After successful EVL, requirement of blood transfusion
|
1 week
|
Adverse drug reaction (ADR)
Time Frame: 1 week
|
Incidence of adverse drug reaction (ADR)
|
1 week
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IEC-INT/2023/Study-865
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Variceal Hemorrhage
-
Kaohsiung Veterans General Hospital.Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC; National Yang-Ming...CompletedVariceal Bleeding, Endoscopic Variceal LigationTaiwan
-
Theodor Bilharz Research InstituteUniversité Libre de BruxellesCompletedVariceal HemorrhageEgypt, Belgium
-
Theodor Bilharz Research InstituteUniversité Libre de BruxellesCompletedVariceal HemorrhageEgypt, Belgium
-
Centre Hospitalier Universitaire, AmiensWithdrawnVariceal Hemorrhage | Haemorrhagic ShockFrance
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
King Abdulaziz Medical CityCompletedVariceal BleedingSaudi Arabia
-
Postgraduate Institute of Medical Education and...CompletedAcute Variceal HaemorrhageIndia
-
Renmin Hospital of Wuhan UniversityNot yet recruitingAcute Variceal BleedingChina
-
Taipei Veterans General Hospital, TaiwanCompleted
Clinical Trials on Terlipressin
-
First Affiliated Hospital, Sun Yat-Sen UniversityCompleted
-
MallinckrodtCompletedHepatorenal SyndromeUnited States
-
Ferring PharmaceuticalsCompletedGastrointestinal Bleeding | Oesophageal VaricesRomania
-
Pere GinesUnknownCirrhosis | Hepatorenal Syndrome Type ISpain
-
Assaf-Harofeh Medical CenterUnknown
-
BioVie Inc.CompletedCirrhosis | Ascites HepaticUnited States
-
Aga Khan UniversityMallinckrodtUnknown
-
Aga Khan UniversityFerozsons Laboratories Ltd.CompletedHemorrhage | Portal Hypertension | Esophageal VaricesPakistan
-
Hospital Clinic of BarcelonaGrant from Education Ministery from 2001-2004.SuspendedCirrhosis | Hepatorenal SyndromeSpain
-
University of PadovaUnknownCirrhosis | Type 1 Hepatorenal SyndromeItaly